<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">642170</article-id><article-id pub-id-type="doi">10.26442/20751753.2024.10.202995</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Statins in the practice of an internal medicine specialist: A review</article-title><trans-title-group xml:lang="ru"><trans-title>Статины в практике терапевта</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3158-286X</contrib-id><name-alternatives><name xml:lang="en"><surname>Susekov</surname><given-names>Andrey V.</given-names></name><name xml:lang="ru"><surname>Сусеков</surname><given-names>Андрей Владимирович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. клинической фармакологии и терапии им. В.Е. Вотчала</p></bio><email>asus99@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Medical Academy of Continuous Professional Education</institution></aff><aff><institution xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-11-23" publication-format="electronic"><day>23</day><month>11</month><year>2024</year></pub-date><volume>26</volume><issue>10</issue><issue-title xml:lang="en">Cardiology and nephrology</issue-title><issue-title xml:lang="ru">Кардиология и нефрология</issue-title><fpage>641</fpage><lpage>648</lpage><history><date date-type="received" iso-8601-date="2024-11-23"><day>23</day><month>11</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-11-23"><day>23</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/642170">https://consilium.orscience.ru/2075-1753/article/view/642170</self-uri><abstract xml:lang="en"><p>Statins have been used in clinical practice for more than 40 years to treat and prevent atherosclerosis and its complications. The results of observational studies indicate that, despite a large evidence base, statins in Russia are still prescribed in low doses, for a maximum of 6 months, leading to a low percentage of achieving the target levels of low-density lipoprotein cholesterol and, thus, to a high residual risk of cardiovascular complications. This paper presents a literature review and analysis of the basic principles of statin therapy in primary prevention, intensive lipid-lowering therapy in patients with very high cardiovascular risk, as well as key safety updates on cholesterol decrease for various organs and systems (liver, kidneys, muscles, nervous system), and carbohydrate metabolism. The article also provides a brief overview of new international guidelines to optimize the diagnosis and treatment of dyslipidemias, which can be useful in the day-to-day practice of an internal medicine specialist.</p></abstract><trans-abstract xml:lang="ru"><p>Статины как основа лечения и профилактики атеросклероза и его осложнений применяются в клинической практике более 40 лет. Результаты наблюдательных исследований свидетельствуют о том, что, несмотря на большую доказательную базу, статины в России по-прежнему назначают в низких дозах, максимум на 6 мес, что ведет к низкому проценту достижения целевых уровней холестерина липопротеинов низкой плотности и, соответственно, к высокому остаточному риску сердечно-сосудистых осложнений. В этой публикации представлен литературный обзор и аналитика основных принципов терапии статинами в первичной профилактике, интенсивной липидснижающей терапии у больных очень высокого сердечно-сосудистого риска, а также ключевые обновления безопасности снижения холестерина по различным органам и системам (печени, почкам, мышцам, нервной системе), углеводному обмену. В статье также представлен краткий обзор новых международных рекомендаций по оптимизации диагностики и лечения дислипидемий, что может быть полезно в повседневной практике терапевта.</p></trans-abstract><kwd-group xml:lang="en"><kwd>primary prevention</kwd><kwd>dyslipidemia</kwd><kwd>statins</kwd><kwd>ezetimibe</kwd><kwd>low-density lipoprotein cholesterol</kwd><kwd>recommendations</kwd><kwd>cardiovascular risk</kwd><kwd>safety</kwd><kwd>diabetes mellitus</kwd><kwd>myopathies</kwd><kwd>hyperenzymemia</kwd><kwd>dementia</kwd><kwd>chronic renal failure</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>первичная профилактика</kwd><kwd>дислипидемия</kwd><kwd>статины</kwd><kwd>эзетимиб</kwd><kwd>холестерин липопротеинов низкой плотности</kwd><kwd>рекомендации</kwd><kwd>сердечно-сосудистый риск</kwd><kwd>безопасность</kwd><kwd>сахарный диабет</kwd><kwd>миопатии</kwd><kwd>гиперферментемия</kwd><kwd>деменция</kwd><kwd>хроническая почечная недостаточность</kwd></kwd-group><funding-group><funding-statement xml:lang="en">This study was supported by KRKA FARMA LLC</funding-statement><funding-statement xml:lang="ru">Материал подготовлен при поддержке компании ООО «КРКА ФАРМА»</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):e285-350. DOI:10.1016/j.jacc.2018.11.003</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Authors/Task Force Members, ESC Committee for Practice Guidelines (CPG). ESC National Cardiac Societies 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140-205. DOI:10.1016/j.atherosclerosis.2019.08.014</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. DOI:10.1093/eurheartj/ehab484</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Нарушения липидного обмена. Клинические рекомендации. 2023. Режим доступа: https://scardio.ru/content/Guidelines/KR_NLO_2023.pdf. Ссылка активна на 23.06.2024 [Narusheniia lipidnogo obmena. Klinicheskie rekomendatsii. 2023. Available at: https://scardio.ru/content/Guidelines/KR_NLO_2023.pdf. Accessed: 23.06.2024 (in Russian)].</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Острый коронарный синдром без подъема сегмента ST кардиограммы. Клинические рекомендации. 2020. Режим доступа: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST-unlocked.pdf. Ссылка активна на 23.06.2024 [Ostryi koronarnyi sindrom bez pod"ema segmenta ST kardiogrammy. Klinicheskie rekomendatsii. 2020. Available at: https://scardio.ru/content/Guidelines/2020/Clinic_rekom_OKS_bST-unlocked.pdf. Accessed: 23.06.2024 (in Russian)].</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Бойцов С.А., Погосова Н.В., Аншелес А.А., и др. Кардиоваскулярная профилактика. Клинические рекомендации. Российский кардиологический журнал. 2023;28(5):5452 [Boytsov SA, Pogosova NV, Ansheles AA, et al. Cardiovascular prevention 2022. Russian national guidelines. Russian Journal of Cardiology. 2023;28(5):5452 (in Russian)]. DOI:10.15829/1560-4071-2023-5452</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Котовская Ю.В., Ткачева О.Н., Сергиенко И.В. Липидснижающая терапия для первичной профилактики у пациентов 75 лет и старше. Консенсус экспертов Российской ассоциации геронтологов и гериатров, Национального общества по изучению атеросклероза, Российского кардиологического общества, Ассоциации клинических фармакологов. Кардиология. 2020;60(6):119-32 [Kotovskaya YV, Tkacheva ON, Sergienko IV. Lipid-lowering therapy for primary cardiovascular prevention in older adults. Consensus Statement of the Russian Association of Gerontologists and Geriatricians, National Society on Atherosclerosis, Russian Society of Cardiology, Association of Clinical Pharmacologists. Kardiologiia. 2020;60(6):119-32 (in Russian)]. DOI:10.18087/cardio.2020.6.n1037</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-97. DOI:10.1056/NEJMoa1410489</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713-22. DOI:10.1056/NEJMoa1615664</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Schwartz GG, Steg GP, Szarek M, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097-107. DOI:10.1056/NEJMoa1801174</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Ray KK, Ference BA, Séverin T, et al. Word Heart Federation Cholesterol Roadmap 2022. Global Heart. 2022;17(1):75. DOI:10.5334/gh.1154</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Romanelli RJ, Ito MK, Karalis DG, et al. Statin utilization and low-density lipoprotein cholesterol in statin-treated patients with atherosclerotic cardiovascular disease: Trends from a community-based health care delivery system, 2002–2016. J Clin Lipidol. 2020;14(3):305-14. DOI:10.1016/j.jacl.2020.03.006</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Navar AN, Kolkailah A, Gillard KK, et al. Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: A retrospective cohort study of 322153 patients. Circ Cardiovasc Qual Outcomes. 2023;16:e009787. DOI:10.1161/CIRCOUTCOMES.122.00978</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Barrios V, Soronen L, Carter A et al. Lipid management across Europe in the real-world setting: A rapid evidence review. Cardiovascular Medicine. Curr Med Res Opin. 2021;37(12):2049-59. DOI:10.1080/03007995.2021.1973396</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Ray K, Haq I, Manu MC; SANTORINI Study Investigators, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: The multinational observational SANTORINI study. Lancet Reg Health Eur. 2023;29:100624. DOI:10.1016/j.lanepe.2023.100624</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Pinto L, Farghaly M, Nunna S, et al. Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates. PLoS One. 2022;17(9):e0268709. DOI:10.1371/journal.pone.0268709</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Guo T, Chu C, Wang C, et al. Lipid goal attainment in diabetes mellitus patients after acute coronary syndrome: A sub analysis of Dyslipidemia International Study II – China. BMC Cardiovasc Disord. 2023;23(1):337. DOI:10.1186/s12872-023-03312-w</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Сусеков А.В. Обоснование повышения доз статинов в повседневной практике. Кардиология. 2024;64(8):79-88 [Susekov AV. Rationale for increasing doses of statins in everyday clinical practice. Kardiologiia. 2024;64(8):79-88 (in Russian)]. DOI:10.18087/cardio.2024.8.n2709</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Драпкина О.М., Имаева А.Э., Куценко В.А., и др. Дислипидемии в Российской Федерации: популяционные данные, ассоциации с факторами риска. Кардиоваскулярная терапия и профилактика. 2023;22(8S):3791 [Drapkina OM, Imaeva AE, Kutsenko VA, et al. Dyslipidemia in the Russian Federation: population data, associations with risk factors. Cardiovascular Therapy and Prevention. 2023;22(8S):3791 (in Russian)]. DOI:10.15829/1728-8800-2023-3791</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Papadaki A, Nolen-Doerr E, Mantzoros CS. The effect of the mediterranean diet on metabolic health: A systematic review and meta-analysis of controlled trials in adults. Nutrients. 2020;12(11):3342. DOI:10.3390/nu12113342</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Сусеков А.В. Актуальные вопросы современной гиполипидемической терапии. Consilium Medicum. 2022;24(1):20-7 [Susekov AV. Topical issues concerning modern lipid-lowering therapy. Consilium Medicum. 2022;24(1):20-7 (in Russian)]. DOI:10.26442/20751753.2022.1.201484</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Сусеков А.В. Современные алгоритмы терапии статинами. Российский кардиологический журнал. 2023;28(10):5594 [Susekov VA. Modern algorithms for statin therapy. Russian Journal of Cardiology. 2023;28(10):5594 (in Russian)]. DOI:10.15829/1560-4071-2023-5594</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Brus S. Clinical evidence of the efficacy of Krka’s rosuvastatin in the treatment of hyperlipidemia with focus on additional doses. Krka Med Farm. 2014;26(38):62-71. DOI:10.15836/ccar.2014.320</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>European patent office. Munich. EP 2 387 566 B1. Available at: https://data.epo.org. Accessed: 17.10.2014.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Сергиенко И.В., Аншелес А.А., Бойцов С.А. Факторы риска, показатели липидного профиля и гиполипидемическая терапия у пациентов различных категорий сердечно-сосудистого риска: данные регистра Атеростоп. Атеросклероз и дислипидемии. 2023;2(51):43-53 [Sergienko IV, Ansheles AA, Boytsov SA. Risk factors, lipid profile indicators and hypolipidemic therapy in patients of various categories of cardiovascular risk: the results of the Aterostop registry. Ateroskleroz i Dislipidemii = The Journal of Atherosclerosis and Dyslipidemias. 2023;2(51):43-53 (in Russian)]. DOI:10.34687/2219-8202.JAD.2023.02.0005</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Рекомендации для врачей по ведению пациентов с дислипидемией и атеросклерозом. Под ред. А.В. Сусекова. М.: Ре Медиа, 2022 [Rekomendatsii dlia vrachei po vedeniiu patsientov s dislipidemiei i aterosklerozom. Pod red. AV Susekova. Moscow: Re Media, 2022 (in Russian)].</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Ramaswami U, Humphries SE, Priestley-Barnham L, еt al. Current management of children and young people with heterozygous familial hypercholesterolaemia – HEART UK statement of care. Atherosclerosis. 2019;290:1-8. DOI:10.1016/j.atherosclerosis.2019.09.005</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Anand SS. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: Systematic review and meta-analysis. Law MR, Wald NJ, Rudnicka AR. BMJ. 2003;326:1407-8. Vasc Med. 2003;8(4):289-90. DOI:10.1191/1358863x03vm518xx</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Orringer CE, Blaha MJ, Blankstein R, еt al. The National Lipid Association scientific statement on coronary artery calcium scoring to guide preventive strategies for ASCVD risk reduction. J Clin Lipidol. 2021;15(1):33-60. DOI:10.1016/j.jacl.2020.12.005</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Kronenberg F, Mora S, Stroes ESG, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement EAS consensus aortic stenosis. Eur Heart J. 2022;43(39):3925-46. DOI:10.1093/eurheartj/ehac361</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Virani SS, Morris PB, Agarwala A, et al. 2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;78(9):960-93. DOI:10.1016/j.jacc.2021.06.011</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Shah NP, Pajidipati NJ, McGarrah RW, et al. Lipoprotein (a): An update on a marker of residual risk and associated clinical manifestations. Am J Cardiol. 2020;126:94-102. DOI:10.1016/j.amjcard.2020.03.043</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Baass A, Paquette M, Bernard S, Hegele RA. Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J Intern Med. 2020;287(4):340-8. DOI:10.1111/joim.13016</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Moulin P, Dufour R, Averna M, et al. Identification and diagnosis of patients with familial chylomicronaemia syndrome (FCS): Expert panel recommendations and proposal of an “FCS score”. Atherosclerosis. 2018;275:265-72. DOI:10.1016/j.atherosclerosis.2018.06.814</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Roeters van Lennep JE, Tokgözoğlu LS, Badimon L, et al. Women, lipids, and atherosclerotic cardiovascular disease: A call to action from the European Atherosclerosis Society. Eur Heart J. 2023;44(39):4157-73. DOI:10.1093/eurheartj/ehad472</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-314. DOI:10.1016/j.kint.2023.10.018</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events a scientific statement from the AHA. Arterioscler Thromb Vasc Biol. 2019;39(2):e38-81. DOI:10.1161/ATV.0000000000000073</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. Eur Heart J. 2018;39(27):2526-39. DOI:10.1093/eurheartj/ehy182</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Rosenson RS, Baker S, Banach M, et al. Optimizing cholesterol treatment in patients with muscle complains. J Am Coll Cardiol. 2017;70(10):290-301. DOI:10.1016/j.jacc.2017.07.752</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Vell MS, Loomba R, Krishman A. Association of statin use with risk of liver disease, hepatocellular carcinoma and liver-related mortality. JAMA Network Open. 2023;6(6):e2320222. DOI:10.1001/jamanetworkopen.2023.20222</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Warden BA, Guyton JR, Kovaks AS, et al. Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association. J Clin Lipidol. 2023;17(1):19-39. DOI:10.1016/j.jacl.2022.09.001</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Goldstein LB, Toth PP, Dearborn-Tomazos JL, et al Aggressive LDL-C lowering and the brain: Impact on risk for dementia and hemorrhagic stroke: A scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2023;43:e404-42. DOI:10.1161/ATV.0000000000000164</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Sattar N. Statins and diabetes: What are the connections? Best Pract Res Clin Endocrinol Metab. 2023;37(3):101749. DOI:10.1016/j.beem.2023.101749</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Bays H, Cohen DE, Chalasani N, et al. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S47-57. DOI:10.1016/j.jacl.2014.02.011</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Assy N, Kaita K, Mymin D, et al. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci. 2000;45(10):1929-34. DOI:10.1023/a:1005661516165</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29(4):412-22. DOI:10.1055/s-0029-1240010</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Björnsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: Reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56(2):374-80. DOI:10.1016/j.jhep.2011.07.023</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Kajinami K, Tsukamoto K, Koba S, et al. Statin Intolerance Clinical Guide 2018. J Atherosclerosis Thromb. 2020;27(4):375-96. DOI:10.5551/jat.50948</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Susekov AV, Korol LA, Watts GF. Bempedoic acid in the treatment of patients with dyslipidemias and statin intolerance. Cardiovasc Drugs Ther. 2021;35(4):841-52. DOI:10.1007/s10557-020-07139-x</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Воевода М.И., Гуревич В.С., Ежов М.В., Сергиенко И.В. Инклисиран – новая эра в гиполипидемической терапии. Кардиология. 2022;62(6):57-62 [Voevoda MI, Gurevich VS, Ezhov MV, Sergienko IV. Inclisiran – a new era in lipid-lowering therapy. Kardiologiia. 2022;62(6):57-62 (in Russian)]. DOI:10.18087/cardio.2022.6.n2115</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Rosenson RS, Baker SK, Jacobson TA, et al.; The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S58-71. DOI:10.1016/j.jacl.2014.03.004</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J Lipid Res. 1993;34:1637-59. PMID:8245716</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Rojas-Fernandez CH, Goldstein LB, Levey AI, et al. An assessment by the Statin Cognitive Safety Task Force 2014 update. J Clin Lipidol. 2014;8(Suppl. 3):S5-16. DOI:10.1016/j.jacl.2014.02.013</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Vance JE. Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Model Mech. 2012;5(6):746-55. DOI:10.1242/dmm.01012</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>de Boer AG, Gaillard PJ. Blood-brain barrier dysfunction and recovery. J Neural Transm (Vienna). 2006;113(4):455-62. DOI:10.1007/s00702-005-0375-4</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE-IT TIMI 22). N Engl J Med. 2004;350(15):1495-504. DOI:10.1056/NEJMoa040583</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Nicholls S, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078-87. DOI:10.1056/NEJMoa1110874</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Nissen S, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity stain therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA. 2006;295(13):1556-65. DOI:10.1001/jama.295.13.jpc60002</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Ballantyne CM, Weiss R, Moccetti T, et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am J Cardiol. 2007;99(5):673-80. DOI:10.1016/j.amjcard.2006.10.022</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Olmastroni E, Molari G, DeBeni N, et al. Statin use and risk of dementia or Alzheimer's disease: A systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29(5):804-14. DOI:10.1093/eurjpc/zwab208</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Wong WB, Lin VW, Boudreau D, Devine EB. Statins in the prevention of dementia and Alzheimer’s disease: A meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf. 2013;22(4):345-58. DOI:10.1002/pds.3381</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й вып. М., 2023 [Algoritmy spetsializirovannoi meditsinskoi pomoshchi bol'nym sakharnym diabetom. Pod red. II Dedova, MV Shestakovoi, AIu Maiorova. 11-i vyp. Moscow, 2023 (in Russian)]. DOI:10.14341/DM13042</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Цыганкова О.В., Евдокимова Н.Е., Байрамова С.С., Сусеков А.В. Статин-ассоциированный рабдомиолиз у женщины 60 лет с декомпенсированным сахарным диабетом 2 типа. Российский кардиологический журнал. 2021;26(11):44171 [Tsygankova OV, Evdokimova NE, Bayramova SS, Susekov AV. Statin-induced rhabdomyolysis in a 60-year-old woman with decompensated type 2 diabetes: A case report. Russian Journal of Cardiology. 2021;26(11):4471 (in Russian)]. DOI:10.15829/1560-4071-2021-4471</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Marx N, Federici M, Schütt K, et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-140. DOI:10.1093/eurheartj/ehad192</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Byrne RA, Rosselo X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-826. DOI:10.1093/eurheartj/ehad191</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Davidson MH. Rosuvastatin safety: lessons from the FDA review and postapproval surveillance. Expert Opin Drug Safety. 2004;3(6):547-57. DOI:10.1517/14740338.3.6.547</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomized placebo-controlled trial. Lancet. 2011;377(9784):2181-92. DOI:10.1016/S0140-6736(11)60739-3</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J. 2010;160(5):785-94.e10. DOI:10.1016/j.ahj.2010.08.012</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Sabouret P, Puymirat E, Kownator S, et al. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice. Panminerva Med. 2023;65(2):244-9. DOI:10.23736/S0031-0808.22.04777-2</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Li JJ, Zhao SP, Zhao D, et al. 2023 China Guidelines for Lipid Management. J Geriatr Cardiology. 2023;20(9):621-63. DOI:10.26599/1671-5411.2023.09.008</mixed-citation></ref><ref id="B71"><label>71.</label><mixed-citation>Araujo F, Caldera D, Aguiar C, et al. Polypill use for the prevention of cardiovascular disease: A position paper. Rev Port Cardiol. 2023;42(10):861-72. DOI:10.1016/j.repc.2023.02.011</mixed-citation></ref><ref id="B72"><label>72.</label><mixed-citation>Puri R, Bansal M, Mehta V, et al. Lipid Association of India 2023 update on cardiovascular risk assessment and lipid management in Indian patients: Consensus statement IV. J Clin Lipidology. 2024;18(3):e315-73. DOI:10.1016/j.jacl.2024.01.006</mixed-citation></ref><ref id="B73"><label>73.</label><mixed-citation>Bangalore S, Fayyad R, Kastelein JJ, et al. 2013 Cholesterol Guidelines Revisited: Percent LDL cholesterol reduction or attained LDL cholesterol level or both for prognosis? Am J Med. 2016;129(4):384-91. DOI:10.1016/j.amjmed.2015.10.024</mixed-citation></ref><ref id="B74"><label>74.</label><mixed-citation>Метельская В.А., Шальнова С.А., Деев А.Д., и др. Анализ распространенности показателей, характеризующих атерогенность спектра липопротеинов, у жителей Российской Федерации (по данным исследования ЭССЕ-РФ). Профилактическая медицина. 2016;1:15-23 [Metelskaya VA, Shalnova SA, Deev AD, et al. Analysis of atherogenic dyslipidemias prevalence among population of Russian Federation (results of the ESSE-RF Study). Russian Journal of Preventive Medicine. 2016;19(1):15-23 (in Russian)]. DOI:10.17116/profmed201619115-23</mixed-citation></ref><ref id="B75"><label>75.</label><mixed-citation>Мешков А.Н., Ершова А.И., Деев А.Д., и др. Распределение показателей липидного спектра у мужчин и женщин трудоспособного возраста в Российской Федерации: результаты исследования ЭССЕ-РФ за 2012–2014 гг. Кардиоваскулярная терапия и профилактика. 2017;16(4):62-7 [Meshkov AN, Ershova AI, Deev AD, et al. Distribution of lipid profile values in economically active men and women in Russian Federation: Results of the Esse-RF Study for the years 2012–2014. Cardiovascular Therapy and Prevention. 2017;16(4):62-7 (in Russian)]. DOI:10.15829/1728-8800-2017-4-62-67</mixed-citation></ref><ref id="B76"><label>76.</label><mixed-citation>Игонина Н.А., Журавлева Е.А., Кондрашева Е.А., и др. Анализ данных массового исследования холестерина у населения (к вопросу о референсных значениях холестерина). Клиническая лабораторная диагностика. 2013;1:11-7 [Igonina NA, Juravleva EA, Kondrasheva EA, et al. The analysis of data of large study of cholesterol level in population: On the issue of reference values of cholesterol). Russian Clinical Laboratory Diagnostics. 2013;1:11-7 (in Russian)].</mixed-citation></ref><ref id="B77"><label>77.</label><mixed-citation>Бойцов С.А., Шахнович Р.М., Терещенко С.Н., и др. Распространенность гиперлипидемии и особенности липидснижающей терапии у пациентов с инфарктом миокарда по данным Российского регистра острого инфаркта миокарда РЕГИОН-ИМ. Кардиология. 2022;62(7):12-22 [Boytsov SA, Shakhnovich RM, Tereschenko SN, et al. The prevalence of hyperlipidemia and features of lipid-lowering therapy in patients with myocardial infarction according to the Russian register of acute myocardial infarction REGION-MI. Kardiologiia. 2022;62(7):12-22 (in Russian)]. DOI:10.18087/cardio.2022.7.n2051</mixed-citation></ref><ref id="B78"><label>78.</label><mixed-citation>Ахмеджанов Н.М., Небиеридзе Д.В., Сафарян А.С., и др. Анализ распространенности гиперхолестеринемии в условиях амбулаторной практики (по данным исследования АРГО): часть I. Рациональная фармакотерапия в кардиологии. 2015;11(3):253-60 [Akhmedzhanov NM, Nebieridze DV, Safaryan AS, et al. Analysis of hypercholesterolemia prevalence in the outpatient practice (according to the ARGO study): Part I. Ration Pharmacother Cardiol. 2015;11(3):253-60 (in Russian)].</mixed-citation></ref><ref id="B79"><label>79.</label><mixed-citation>Оганов Р.Г., Кухарчук В.В., Арутюнов Г.П., и др. Сохраняющиеся нарушения показателей липидного спектра у пациентов с дислипидемией, получающих статины, в реальной клинической практике в Российской Федерации (российская часть исследования DYSIS). Кардиоваскулярная терапия и профилактика. 2012;11(4):70-8 [Oganov RG, Kukharchuk VV, Arutyunov GP, et al. Persistent dyslipidemia in statin-treated patients: Russian real-world clinical practice data (Russian part of the DYSIS Study). Cardiovascular Therapy and Prevention. 2012;11(4):70-8 (in Russian)].</mixed-citation></ref></ref-list></back></article>
